Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Posted: 6 May 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces initial encouraging data from EFTISARC-NEO, a Phase II investigator-initiated…
DIMERIX RECEIVES APPROVAL FOR PAEDIATRIC INVESTIGATION PLAN FROM THE UK MHRA
Posted: 6 May 2024 Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company with late-stage clinical assets, today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its Paediatric Investigation Plan (PIP) for…
One-two punch treatment delivers blood cancer knockout
Posted: 6 May 2024 A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancers. A new study by WEHI…
Trofinetide New Drug Submission for Rett Syndrome Accepted for Priority Review by Health Canada
Posted: 1 May 2024 Neuren Pharmaceuticals (ASX: NEU) is pleased to report that Health Canada has accepted for review the New Drug Submission (NDS) of trofinetide for the treatment of Rett syndrome, that was submitted by Neuren’s global…
COMPLETION OF EYE AND EAR REDEVELOPMENT A TRUE VISION
Posted: 1 May 2024 The redevelopment of Australia’s only specialist eye, ear, nose and throat hospital is now complete, with the world class specialist health, research and education facility bigger and better than before. Minister for Health Infrastructure…
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
Posted: 1 May 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that important new data on its lead drug candidate ATH434…
Vic sees 34% increase in digital health startups
Posted: 1 May 2024 Victoria has seen a 34% increase in digital health startups in the past year, according to the latest data from commercialisation firm ANDHealth. Investment and support from the Victorian Government for digital health programs like LaunchVic,…
Funding success accelerating cardiovascular research
Posted: 1 May 2024 More than $800,000 in seed funding has been awarded to four Monash Victorian Heart Institute partnered research teams in Round 1 of the Australian Stroke and Heart Research Accelerator (ASHRA) Seed Funding Scheme. The ASHRA Centre…
BioCurate to continue collaboration with Monash University researchers to develop a new treatment for Inflammatory Bowel Disease
Posted: 1 May 2024 A research project supported by BioCurate’s Proof of Concept fund led by Monash University will move into the next exciting phase as an exclusive licence in the BioCurate Portfolio. The research, led by Monash…
World class scanner to diagnose and treat cancers earlier
Posted: 1 May 2024 Patients at the new Paula Fox Melanoma and Cancer Centre at Melbourne’s Alfred Hospital will have access to cutting-edge scanning technology that will be able to detect cancers earlier. The Albanese Government is investing…
Improving outcomes for a rare form of lung cancer
Posted: 1 May 2024 A clinical trial led by a Peter Mac medical oncologist has demonstrated the benefits of a new lung cancer treatment, and these practise-changing results have just published in the New England Journal of Medicine.…
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA® (pembrolizumab) in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Posted: 1 May 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces preliminary topline results from Cohort B of the TACTI-003…
